Bloomberg BNA’s Corporate Law & Accountability Report is available on the Corporate Law Resource Center. This news service keeps corporate practitioners informed of legal developments of...
May 19 — The Delaware Chancery Court May 19 put the brakes on a plan to shrink Cogentix Medical Inc.'s board from seven to five directors.
Vice Chancellor J. Travis Laster granted a preliminary injunction preventing Cogentix directors from implementing a board reduction plan at its May 20 annual meeting. Laster found that Cogentix directors acted inequitably in attempting to reconstitute the structure of the company's board.
“For good or ill, the Company's stockholders—not this court—have the right to elect the individuals who, as members of the board, will direct and oversee the business and affairs of the corporation,” Laster wrote. “The preliminary injunction preserves their right to do that, pending the final disposition of the case.”
The lawsuit arose from a leadership dispute at Cogentix, a company that was formed from the merger between Vision-Sciences Inc. (VSI) and Uroplasty Inc.
Cogentix's board consisted of both former VSI and Uroplasty directors. According to the court's opinion, Cogentix director and incumbent chief executive officer Robert Kill and other directors aligned with him developed the reduction plan to preserve control over the company in the face of an anticipated proxy contest from another director, Lewis Pell. Kill was the former CEO and president of Uroplasty and Pell was a co-founder and former chairman of VSI.
Pell sued Kill to stop the plan.
The court found that Pell had established a reasonable probability of success on his claims. In reaching this conclusion, the court applied enhanced scrutiny—a tougher standard of review compared to the business judgment rule—to Kill and his co-defendants.
Laster said that the reduction plan had a “clear and obvious effect” on the ability of stockholders to replace incumbent directors. He also determined that the enhanced scrutiny standard applied because the plan touched on matters of corporate control.
“Both types of conduct are sufficiently suspect to warrant review under the enhanced scrutiny test,” he said.
To contact the reporter on this story: Michael Greene in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Yin Wilczek at email@example.com
The opinion is available at http://www.bloomberglaw.com/public/document/Pell_v_Kill_No_12251VCL_2016_BL_159454_Del_Ch_May_19_2016_Court_O.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)